Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer
Abstract We sought to determine whether sequencing of treatment impacted outcomes in older, comorbid patients. Using the National Cancer Database(2010–2017), 2911 patients >70 with a Charleson Deyo Comorbidity(CCDM) score of 2/3 and cT1c-3/N0-3/HER2 positive or triple-negative breast cancer treat...
Saved in:
| Main Authors: | Nina Tamirisa, Wenli Dong, Yu Shen, Heather Lin, Simona F. Shaitelman, Gildy Babiera, Isabelle Bedrosian |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-025-00732-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative
by: Su-Jin Shin, et al.
Published: (2024-11-01) -
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
by: Ami N Shah, et al.
Published: (2020-05-01) -
Effect of HER2-low expression on the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer
by: Lin-Yu Xia, et al.
Published: (2025-06-01) -
Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancer
by: Andrés F. Bedoya-López, et al.
Published: (2025-08-01) -
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
by: Fatima Cardoso, et al.
Published: (2024-12-01)